Results: A total of 16 Japanese and 11 Caucasian subjects participated in this study. No deaths, serious adverse events (AEs) , or discontinuations due to AEs occurred. Frequently reported treatment-emergent AEs (TEAEs) were somnolence, dizziness, and hypoesthesia. The frequency of TEAEs in Japanese subjects was higher and dose-dependent compared with Caucasian subjects, in whom no such trend was observed. However, the Japanese AE data was comparable to an integrated summary of TEAEs in 556 non-Japanese healthy subjects with similar doses of lasmiditan administration. Increases in exposure to lasmiditan were observed with increasing dose. The pharmacokinetics of lasmiditan were similar between Japanese and Caucasian subjects, with a mean half-life of approximately 4 hours.